Ocugen, Inc. Stock price

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:33:54 2024-03-28 am EDT 5-day change 1st Jan Change
1.715 USD -3.65% Intraday chart for Ocugen, Inc. +28.36% +199.13%
Sales 2023 * - Sales 2024 * - Capitalization 457M
Net income 2023 * -69M Net income 2024 * -66M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-6.28 x
P/E ratio 2024 *
-6.21 x
Employees 84
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.5%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Ocugen, Inc.

1 day+2.89%
1 week+43.55%
Current month+90.17%
1 month+79.80%
3 months+229.63%
6 months+337.67%
Current year+209.57%
More quotes
1 week
1.41
Extreme 1.41
2.11
1 month
0.80
Extreme 0.802
2.11
Current year
0.49
Extreme 0.4905
2.11
1 year
0.35
Extreme 0.345
2.11
3 years
0.35
Extreme 0.345
17.65
5 years
0.17
Extreme 0.17
18.77
10 years
0.17
Extreme 0.17
18.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 12-12-31
Director of Finance/CFO 42 -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 76 22-03-16
Director/Board Member 74 20-04-04
Director/Board Member 68 19-09-26
More insiders
Date Price Change Volume
24-03-28 1.725 -3.09% 2 483 118
24-03-27 1.78 +2.89% 10,594,790
24-03-26 1.73 -5.46% 27,657,700
24-03-25 1.83 +11.59% 44,074,756
24-03-22 1.64 +22.39% 32,005,125

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.78 USD
Average target price
6.333 USD
Spread / Average Target
+255.81%
Consensus
  1. Stock
  2. Equities
  3. Stock Ocugen, Inc. - Nasdaq